Q32 Bio (QTTB) Projected to Post Earnings on Tuesday

Q32 Bio (NASDAQ:QTTB) will likely be releasing its earnings data before the market opens on Tuesday, March 11th. Analysts expect Q32 Bio to post earnings of ($1.25) per share for the quarter.

Q32 Bio Trading Down 4.7 %

QTTB stock opened at $2.22 on Friday. The company has a debt-to-equity ratio of 0.61, a current ratio of 6.53 and a quick ratio of 6.53. Q32 Bio has a 12 month low of $2.04 and a 12 month high of $53.79. The firm’s 50-day moving average is $2.98 and its 200 day moving average is $24.22. The company has a market capitalization of $27.04 million, a PE ratio of -0.16 and a beta of -0.27.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Guggenheim lowered shares of Q32 Bio from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 11th. Raymond James reiterated an “outperform” rating and issued a $22.00 price objective (down from $90.00) on shares of Q32 Bio in a research report on Wednesday, December 11th. Wells Fargo & Company reissued an “equal weight” rating and issued a $16.00 target price (down previously from $95.00) on shares of Q32 Bio in a report on Wednesday, December 11th. Leerink Partnrs downgraded Q32 Bio from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 11th. Finally, BMO Capital Markets downgraded Q32 Bio from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $22.00 to $3.00 in a report on Tuesday, February 11th. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $24.86.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.